Related Experiment Video
Updated: Jun 7, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 31, 2013
[Campto (CPT-11) treatment of advanced large intestinal cancer: clinical experience]
Li Zhang1,
1Cancer Center of Sun Yat-sen University, Guangzhou 510060, China.
Objective:
To evaluate the efficacy and toxicity of campto (CPT-11) monotherapy or combined with 5Fu + leucovorin (CF) in advanced large intestinal cancer.
Methods:
186 such patients were divided into campto monotherapy group and CPT-11 plus 5Fu + CF [De Gramont (DGM) or Mayo protocal] groups. The mean dose of CPT-11 was 270 mg/m(2) alone in the monotherapy group and 150 mg/m(2) in the combination group. Campto was given as iv infusion in no less than 30-minutes.
Results:
186 patients were eligible for response evaluation. The response rates were 27.9% in the monotherapy group, 32.7% in CPT-11 + DGM and 27.3% in CPT-11 + Mayo group. For 55 untreated patients, the response rates of monotherapy, Campto + DGM and Campto + Mayo regime groups were 33.3%, 28.9% and 50.0%. For 131 treated patients, they were 26.4%, 34.8% and 22.2%, respectively. The toxicities of the whole group were 16.0% cholinergic syndrome, 51.9% delayed diarrhea and 19.8% leucopenia. There were 2 treatment-related deaths.
Conclusion:
The efficacy and toxicities of campto are similar as compared with the reports by other investigators.
Related Concept Videos
Treatment Resistant Cancers
Treatment Resistent Cancers
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Chronic Pancreatitis II: Collaborative Care
Assessment:

